Neurocrine Biosciences (NBIX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$155.14+0.01%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Neurocrine grew revenue 42% in Q1 2026. It aims for $2.75 billion revenue in 2026. The Soleno acquisition expands rare disease products. New data boosts CRENESSITY sales.
Growth could slow if new products fail. Debt from acquisition may strain finances. Competition might reduce market share.
The price is about 7% below our fair value near $190. Analysts expect 28% revenue growth, which we agree with.
Breaks if: Debt levels become unsustainable or credit facility not secured
Breaks if: Revenue growth falls below 20% YoY in FY26
Revenue falls below $2.5 billion in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on expanding its commercial portfolio and advancing its clinical pipeline. The current thesis state is intact, supported by strong revenue growth and successful integration of acquisitions.
The market appears to have priced in a neutral valuation, with NBIX being considered cheap compared to its peers. There is an expectations gap suggesting that the market may not fully recognize the potential for continued revenue growth and successful pipeline advancements.
Fundamentals are likely to show continued strong revenue growth, driven by recent sales increases from key products. However, there is a moderate risk of missing earnings expectations, particularly given the recent trend of misses among industry peers.
The long-term thesis hinges on the company's ability to maintain guidance and avoid credibility issues, especially after recent upward revisions. Additionally, the performance of sector bellwethers and overall economic conditions will be crucial in determining the trajectory of NBIX.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the growth story. However, safety concerns about Vykat could hinder the advancement of the clinical pipeline.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Acquisition fails or is reversed
In the next 1 to 3 years, NBIX's performance will depend on its execution of growth strategies and external market conditions. Not investment advice.